TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS)

SIMPLE SUMMARY: T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) acts as an immune checkpoint on exhausted T cells and has been associated with dismal outcomes in various solid tumors. TIM3 is currently being evaluated as an immunotherapeutic target in multiple clinical trials. Ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Berclaz, Luc M., Altendorf-Hofmann, Annelore, Lindner, Lars H., Burkhard-Meier, Anton, Di Gioia, Dorit, Dürr, Hans Roland, Klein, Alexander, Albertsmeier, Markus, Schmidt-Hegemann, Nina-Sophie, Klauschen, Frederick, Knösel, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216414/
https://www.ncbi.nlm.nih.gov/pubmed/37345075
http://dx.doi.org/10.3390/cancers15102735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216414/
https://www.ncbi.nlm.nih.gov/pubmed/37345075
http://dx.doi.org/10.3390/cancers15102735

Ejemplares similares